Marburg Drug Shows Promise

Monkeys infected with lethal doses of Marburg virus were rescued by an experimental siRNA-based therapeutic, a study shows.

Written byJyoti Madhusoodanan
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

FLICKR, AJCANNAn experimental drug rescued monkeys infected with lethal doses of a virus closely related to Ebola even when given days after the infection occurred, according to research published this week (August 22) in Science Translational Medicine.

Like Ebola, Marburg virus infections also cause a deadly hemorrhagic fever that is fatal in 90 percent of affected individuals. Canadian company Tekmira Pharmaceuticals’ experimental medicine, TKM-Marburg, uses short interfering RNAs (siRNAs) encapsulated in nanoparticles, which block viral genes to treat infections. Earlier this month, the firm’s experimental drug TKM-Ebola was green-lighted by the US Food and Drug Administration for potential use to treat people with Ebola virus disease.

Researchers led by Thomas Geisbert of the University of Texas in Galveston and his colleagues from Tekmira infected 21 rhesus monkeys with potentially lethal doses of a virulent strain of Marburg. Groups of the monkeys were given the siRNA drug at different times after infection, ranging from 30 minutes to three days. All animals that received ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies